Bispecific CD20-directed CD3 T Cell Engager drugs

2 medications in the FDA established pharmacologic class “Bispecific CD20-directed CD3 T Cell Engager”.

DrugTypeNDC products
Columvi
Glofitamab
Rx2
Epkinly
epcoritamab-bysp
Rx2